Lu Xu

898 total citations
37 papers, 592 citations indexed

About

Lu Xu is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Lu Xu has authored 37 papers receiving a total of 592 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Molecular Biology, 24 papers in Cancer Research and 9 papers in Oncology. Recurrent topics in Lu Xu's work include Cancer-related molecular mechanisms research (14 papers), RNA modifications and cancer (11 papers) and MicroRNA in disease regulation (10 papers). Lu Xu is often cited by papers focused on Cancer-related molecular mechanisms research (14 papers), RNA modifications and cancer (11 papers) and MicroRNA in disease regulation (10 papers). Lu Xu collaborates with scholars based in China, United States and Macao. Lu Xu's co-authors include Zhi Li, Yuee Teng, Xiujuan Qu, Xiaofang Che, Kezuo Hou, Sha Shi, Yunpeng Liu, Hui Cong, Yuan Sheng and Hengyu Li and has published in prestigious journals such as The FASEB Journal, Biochemical and Biophysical Research Communications and Frontiers in Immunology.

In The Last Decade

Lu Xu

34 papers receiving 590 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lu Xu China 15 463 363 97 69 47 37 592
Shu‐Qiang Zhu China 11 562 1.2× 389 1.1× 116 1.2× 77 1.1× 35 0.7× 24 678
Haoyi Jin China 13 402 0.9× 299 0.8× 108 1.1× 78 1.1× 23 0.5× 19 541
Yanmei Cui China 13 450 1.0× 333 0.9× 138 1.4× 77 1.1× 70 1.5× 16 641
Yuanhe Wang China 12 374 0.8× 311 0.9× 150 1.5× 82 1.2× 34 0.7× 43 576
Mengxi Huang China 15 428 0.9× 195 0.5× 169 1.7× 90 1.3× 66 1.4× 31 655
Jingdong He China 16 650 1.4× 546 1.5× 140 1.4× 90 1.3× 38 0.8× 29 829
Hee Doo Yang South Korea 13 479 1.0× 279 0.8× 80 0.8× 61 0.9× 43 0.9× 18 607
Meisongzhu Yang China 12 386 0.8× 220 0.6× 104 1.1× 114 1.7× 29 0.6× 16 524
Wenzheng Yuan China 8 304 0.7× 176 0.5× 179 1.8× 64 0.9× 49 1.0× 8 458

Countries citing papers authored by Lu Xu

Since Specialization
Citations

This map shows the geographic impact of Lu Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lu Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lu Xu more than expected).

Fields of papers citing papers by Lu Xu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lu Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lu Xu. The network helps show where Lu Xu may publish in the future.

Co-authorship network of co-authors of Lu Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Lu Xu. A scholar is included among the top collaborators of Lu Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lu Xu. Lu Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yang, Jiao, Xing Zhang, Lian Duan, et al.. (2025). Association of plasma zinc and copper levels with mild cognitive impairment in patients with type 2 diabetes. Frontiers in Nutrition. 12. 1532080–1532080. 1 indexed citations
2.
Li, Heming, Lu Xu, Tao Han, et al.. (2024). Exploring new frontiers: cell surface vimentin as an emerging marker for circulating tumor cells and a promising therapeutic target in advanced gastric Cancer. Journal of Experimental & Clinical Cancer Research. 43(1). 129–129. 11 indexed citations
3.
Li, Xin, et al.. (2024). FGL1: a novel biomarker and target for non-small cell lung cancer, promoting tumor progression and metastasis through KDM4A/STAT3 transcription mechanism. Journal of Experimental & Clinical Cancer Research. 43(1). 213–213. 4 indexed citations
4.
5.
6.
Wang, Jian, et al.. (2023). Development and Validation of a Prognosis-Prediction Signature for Patients with Lung Adenocarcinoma Based on 11 Telomere-Related Genes. Frontiers in Bioscience-Landmark. 28(10). 254–254. 1 indexed citations
7.
Shi, Tao, et al.. (2022). LncRNA PVT1 facilitates DLBCL development via miR-34b-5p/Foxp1 pathway. Molecular and Cellular Biochemistry. 477(3). 951–963. 11 indexed citations
8.
Xu, Lu, Jianxin Lü, Siqi Wang, et al.. (2021). Circulating Serum Exosomal miR-92a-3p as a Novel Biomarker for Early Diagnosis of Gastric Cancer. Future Oncology. 17(8). 907–919. 29 indexed citations
9.
Xu, Lu, Jinglei Qu, Na Song, et al.. (2021). FEN1 is a prognostic biomarker for ER+ breast cancer and associated with tamoxifen resistance through the ERα/cyclin D1/Rb axis. Annals of Translational Medicine. 9(3). 258–258. 17 indexed citations
10.
Zhang, Hongliang, Jinliang Wang, Junyan Zhang, et al.. (2021). Identification of the Signature Associated With m6A RNA Methylation Regulators and m6A-Related Genes and Construction of the Risk Score for Prognostication in Early-Stage Lung Adenocarcinoma. Frontiers in Genetics. 12. 656114–656114. 12 indexed citations
11.
12.
Zhang, Xiaofen, Lu Xu, Wanlei Gao, et al.. (2020). A label-free microfluidic chip for the highly selective isolation of single and cluster CTCs from breast cancer patients. Translational Oncology. 14(1). 100959–100959. 23 indexed citations
13.
Xu, Lu, Zizheng Wang, Chengliang Yin, et al.. (2020). Long noncoding RNA LINC02580 suppresses the invasion–metastasis cascade in hepatocellular carcinoma by targeting SRSF1. Biochemical and Biophysical Research Communications. 533(4). 685–691. 9 indexed citations
14.
15.
Xing, Xin, Ti Wen, Mingming Deng, et al.. (2020). Inhibition of FEN1 Increases Arsenic Trioxide-Induced ROS Accumulation and Cell Death: Novel Therapeutic Potential for Triple Negative Breast Cancer. Frontiers in Oncology. 10. 425–425. 24 indexed citations
16.
Xu, Lu, Ying Wu, Xiaofang Che, et al.. (2019). Cox-LASSO Analysis Reveals a Ten-lncRNA Signature to Predict Outcomes in Patients with High-Grade Serous Ovarian Cancer. DNA and Cell Biology. 38(12). 1519–1528. 13 indexed citations
17.
Zhou, Lu, Zhi Li, Bowen Yang, et al.. (2019). Prognostic value of long non-coding RNA FOXD2-AS1 expression in patients with solid tumors. Pathology - Research and Practice. 215(9). 152449–152449. 4 indexed citations
18.
Li, Ce, Qian Dong, Xiaofang Che, et al.. (2018). MicroRNA-29b-2-5p inhibits cell proliferation by directly targeting Cbl-b in pancreatic ductal adenocarcinoma. BMC Cancer. 18(1). 681–681. 20 indexed citations
19.
20.
Wang, Jianwei, Lina Zhou, Zhi Li, et al.. (2015). YY1 suppresses FEN1 over-expression and drug resistance in breast cancer. BMC Cancer. 15(1). 50–50. 53 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shu‐Qiang Zhu Breakdown of academic impact, for papers by Haoyi Jin Breakdown of academic impact, for papers by Yanmei Cui Breakdown of academic impact, for papers by Yuanhe Wang Breakdown of academic impact, for papers by Mengxi Huang Breakdown of academic impact, for papers by Jingdong He Breakdown of academic impact, for papers by Hee Doo Yang Breakdown of academic impact, for papers by Meisongzhu Yang Breakdown of academic impact, for papers by Wenzheng Yuan
Rankless by CCL
2026